Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vitamin B3 pill undo early heart damage from childhood adversity?

NCT ID NCT07073352

Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial investigates whether a form of vitamin B3 called nicotinamide riboside (NR) can improve blood vessel function in young adults who experienced four or more adverse childhood experiences (ACEs). Researchers believe ACEs may accelerate vascular aging by lowering SIRT1, a protein that protects blood vessels, and NR may boost SIRT1 activity. The study includes young adults aged 18-30 with and without ACEs, and involves a 4-week NR supplementation period. The goal is to see if NR can restore blood vessel health and potentially reduce future heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide riboside, a vitamin B3 derivative that boosts NAD+ levels to support SIRT1 activity
What this could lead to
If it works, this could point toward a dietary supplement that helps reverse early blood vessel damage linked to childhood adversity, potentially lowering future heart disease risk.
What could go wrong
This is a small, early proof-of-concept study. The supplement may not improve blood vessel function, and results may not apply to everyone. Side effects are possible, though NR is generally well-tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 - 30 years * ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2) Exclusion Criteria: * Resting arterial blood pressure \>140/90 mmHg * BMI ≥30 kg/m2 and/or weight unstable (\>2.27 kg change) last 6 month * Cardiovascular, metabolic, or pulmonary disease * Cardiovascular or metabolic prescription drug use * Vasoactive antidepressant drug use (SSRIs and clonidine) * Currently pregnant or breastfeeding * Heavy alcohol consumption (AUDIT screening) * Use of illicit drugs * Current tobacco use * Regular vigorous (\>6 MET s) aerobic exercise (\>4 bouts/week, \>30 min/bout) * Dietary supplementation with antioxidants or habitual use of NSAIDs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse childhood experiences are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse childhood experiences Endothelial dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Kinesiology, University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53706, United States

  • Integrative Laboratory of Applied Physiology and Lifestyle Medicine

    COMPLETED

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.